heart failure glp-1 The Cardiovascular Biology of Glucagon-like Peptide-1 GLP-1 medications are not just

Emerging assets like the obesity candidate MariTide (maridebart cafraglutide) are attracting investor interest, and Amgen is defending core products against biosimilar competition

GLP-1s: Seizing Opportunity in a New CPG Landscape leads you through a detailed exploration of the GLP-1 user journey, delivering a consumer-centric understanding of the attitudinal, behavioral, commercial and cultural disruption emerging from GLP-1 adoption

1 and Supplementary Fig

For semaglutide injections, the FDA determined the shortage was resolved in February 2025 and subsequently laid out time-limited enforcement discretion windows

[DOI] [Google Scholar] 11

These nutritional concerns are particularly relevant in patients experiencing prolonged or severe appetite suppression